Neuropsychologic Impact of Standard-Dose Systemic Chemotherapy in Long-Term Survivors of Breast Cancer and Lymphoma By Tim A. Ahles, Andrew J. Saykin, Charlotte T. Furstenberg, Bernard Cole, Leila A. Mott, Karen Skalla, Marie B. Whedon, Sarah Bivens, Tara Mitchell, E. Robert Greenberg, Peter M. Silberfarb From the Department of Psychiatry and Center for Psycho-Oncology Research, Department of Psychiatry (Neuropsychology Program), Community and Family Medicine, and Norris Cotton Cancer Center, New Hampshire Hospital, Concord, NH. Address reprint requests to Tim A. Ahles, PhD, Department of Psychiatry, Dartmouth-Hitchcock Medical Center, One Medical Center Dr, Lebanon, NH 03756; email: Tim.A.Ahles@dartmouth.edu. PURPOSE: The primary purpose of this study was to compare the neuropsychologic functioning of long-term survivors of breast cancer and lymphoma who had been treated with standard-dose systemic chemotherapy or local therapy only. PATIENTS AND METHODS: Long-term survivors (5 years postdiagnosis, not presently receiving cancer treatment, and disease-free) of breast cancer or lymphoma who had been treated with systemic chemotherapy (breast cancer: n = 35, age, 59.1 ± 10.7 years; lymphoma: n = 36, age, 55.9 ± 12.1 years) or local therapy only (breast cancer: n = 35, age, 60.6 ± 10.5 years; lymphoma: n = 22, age, 48.7 ± 11.7 years) completed a battery of neuropsychologic and psychologic tests (Center for Epidemiological Study–Depression, Spielberger State-Trait Anxiety Inventory, and Fatigue Symptom Inventory). RESULTS: Multivariate analysis of variance, controlling for age and education, revealed that survivors who had been treated with systemic chemotherapy scored significantly lower on the battery of neuropsychologic tests compared with those treated with local therapy only (P < .04), particularly in the domains of verbal memory (P < .01) and psychomotor functioning (P < .03). Survivors treated with systemic chemotherapy were also more likely to score in the lower quartile on the Neuropsychological Performance Index (39% v 14%, P < .01) and to self-report greater problems with working memory on the Squire Memory Self-Rating Questionnaire (P < .02). CONCLUSION: Data from this study support the hypothesis that systemic chemotherapy can have a negative impact on cognitive functioning as measured by standardized neuropsychologic tests and self-report of memory changes. However, analysis of the Neuropsychological Performance Index suggests that only a subgroup of survivors may experience long-term cognitive deficits associated with systemic chemotherapy. Journal of Clinical Oncology, Vol 20, Issue 2 (January), 2002: 485-493 © 2002 American Society for Clinical Oncology 2/02 Reuters Health Curr Opin Oncol, 7/06 Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.